^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
grapiprant (RQ-00000007)
i
Other names: RQ-00000007, RQ-7, AAT-007, 423, ARY 007, CJ-023, CJ-023,423, CJ-23423, MR-10A7, IK-007, ARYS-007, RQ-07, CJ023,423, RMX1002, 3D-1002, 3D1002, CJ 023,423
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
3DMed, AskAt, HaiHe Biopharma, ImageneBio, Maruishi Pharma, Ningbo Tai Kang
Drug class:
PGE4 antagonist
Related drugs:
1year
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain (clinicaltrials.gov)
P2, N=177, Not yet recruiting, 3D Medicines | Phase classification: P2a/2b --> P2 | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Dec 2025
Phase classification • Trial completion date • Trial primary completion date • Combination therapy
|
grapiprant (RQ-00000007)
1year
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer (clinicaltrials.gov)
P1/2, N=6, Terminated, M.D. Anderson Cancer Center | N=25 --> 6 | Trial completion date: Dec 2025 --> Sep 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Sep 2024; The sponsor terminated support for this study
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
|
HER-2 positive • HER-2 negative
|
Halaven (eribulin mesylate) • grapiprant (RQ-00000007)
2years
KEYNOTE-878: Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer (clinicaltrials.gov)
P1b, N=54, Completed, Arrys Therapeutics | Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> Mar 2023 | Trial primary completion date: Jun 2022 --> Mar 2023
Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • MUC16 (Mucin 16, Cell Surface Associated)
|
Keytruda (pembrolizumab) • grapiprant (RQ-00000007)
over2years
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer (clinicaltrials.gov)
P1/2, N=25, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
|
HER-2 positive • HER-2 negative
|
Halaven (eribulin mesylate) • grapiprant (RQ-00000007)
over3years
KEYNOTE-878: Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer (clinicaltrials.gov)
P1b, N=54, Active, not recruiting, Arrys Therapeutics | Trial completion date: Jun 2022 --> Sep 2022 | Trial primary completion date: Mar 2022 --> Jun 2022
Trial completion date • Trial primary completion date • Combination therapy
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • MUC16 (Mucin 16, Cell Surface Associated)
|
Keytruda (pembrolizumab) • grapiprant (RQ-00000007)
over3years
KEYNOTE-878: Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer (clinicaltrials.gov)
P1b, N=54, Active, not recruiting, Arrys Therapeutics | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • MUC16 (Mucin 16, Cell Surface Associated)
|
Keytruda (pembrolizumab) • grapiprant (RQ-00000007)
4years
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer (clinicaltrials.gov)
P1/2, N=25, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
|
HER-2 positive • HER-2 negative
|
Halaven (eribulin mesylate) • grapiprant (RQ-00000007)
4years
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer (clinicaltrials.gov)
P1/2, N=25, Not yet recruiting, M.D. Anderson Cancer Center
New P1/2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
|
HER-2 positive • HER-2 negative
|
Halaven (eribulin mesylate) • grapiprant (RQ-00000007)
over4years
KEYNOTE-878: Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer (clinicaltrials.gov)
P1b, N=58, Recruiting, Arrys Therapeutics | Trial completion date: Nov 2021 --> Jun 2022 | Trial primary completion date: Jul 2021 --> Mar 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • MUC16 (Mucin 16, Cell Surface Associated)
|
Keytruda (pembrolizumab) • grapiprant (RQ-00000007)
over4years
NFκB-Activated COX2/PGE/EP4 Axis Controls the Magnitude and Selectivity of BCG-Induced Inflammation in Human Bladder Cancer Tissues. (PubMed, Cancers (Basel))
While NFκB blockade suppressed both the desirable and undesirable components of BCG-driven inflammation, the inhibitors of PGE synthesis (Celecoxib or Indomethacin) or signaling (EP4-selective blocker, ARY-007), selectively eliminated the induction of MDSC/Treg attractants and immunosuppressive factors but enhanced the production of CTL attractants, CCL5, CXCL9 and CXCL10. PGE blockade allowed for the selectively enhanced migration of CTLs to the BCG-treated BlCa samples and eliminated the enhanced migration of Tregs. Since the balance between the CTLs and suppressive cells in the TME predicts the outcomes in patients with BlCa and other diseases, our data help to elucidate the mechanisms which limit the effectiveness of BCG therapies and identify new targets to enhance their therapeutic effects.
Journal
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL22 (C-C Motif Chemokine Ligand 22) • NOS2 (Nitric Oxide Synthase 2)
|
celecoxib oral • grapiprant (RQ-00000007)
almost5years
KEYNOTE-888: Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma (clinicaltrials.gov)
P1b/2, N=18, Terminated, Arrys Therapeutics | Trial completion date: Nov 2021 --> Feb 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2021 --> Feb 2021; Based on the totality of the generated combined safety and efficacy data in the interim period, the company decided to terminate the combination study in NSCLC patients. There are no subjects on study drug at this time or in the EOT Follow-up period.
Clinical • Trial completion date • Trial termination • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
Keytruda (pembrolizumab) • grapiprant (RQ-00000007)
almost5years
KEYNOTE-888: Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma (clinicaltrials.gov)
P1b/2, N=18, Active, not recruiting, Arrys Therapeutics | Recruiting --> Active, not recruiting | N=41 --> 18
Clinical • Enrollment closed • Enrollment change • Combination therapy • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
Keytruda (pembrolizumab) • grapiprant (RQ-00000007)
Share via
